Literature DB >> 9314965

Hepatocellular carcinoma: the role of helical biphasic contrast-enhanced CT versus CT during arterial portography.

M Kanematsu1, J H Oliver, B Carr, R L Baron.   

Abstract

PURPOSE: To assess the role of helical biphasic computed tomography (CT) versus CT during arterial portography (CTAP) in the detection of hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Helical biphasic CT and CTAP examinations were performed in 33 patients with biopsy-proved HCC. Three blinded radiologists retrospectively evaluated portal venous phase images, portal venous phase plus hepatic arterial phase images (helical biphasic CT), and CTAP plus portal venous phase images at separate sittings. In 23 patients with pathologic proof of total tumor burden, the readers conducted a consensus matched-pair reading to determine the sensitivity of each method.
RESULTS: In the 23 patients with a proved tumor burden of 100 HCC lesions, the observers detected 74 tumors on portal venous phase images, 82 tumors on hepatic arterial phase images, 87 tumors on CTAP images, 87 tumors on helical biphasic CT images, and 96 tumors on portal venous phase plus CTAP images. Hepatic arterial phase images and CTAP images, respectively, depicted 13 and 23 tumors not seen on portal venous phase images in eight (35%) and 13 (56%) of 23 patients. Ten tumors were seen on portal venous phase images but not on CTAP images owing to the presence of central tumors or segmental portal venous thrombi that obstructed the flow of contrast material to more peripheral portions of the liver.
CONCLUSION: The addition of hepatic arterial phase imaging to portal venous phase imaging (helical biphasic CT) provided an incrementally increased yield in HCC tumor detection. Helical biphasic CT should be used as the initial screening examination in patients with suspected or known HCC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314965     DOI: 10.1148/radiology.205.1.9314965

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

1.  Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography.

Authors:  Kazunori Kubota; Hiroyasu Ina; Yoichi Okada; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

2.  Optimizing scan timing of hepatic arterial phase by physiologic pharmacokinetic analysis in bolus-tracking technique by multi-detector row computed tomography.

Authors:  Isao Yamaguchi; Eiji Kidoya; Masayuki Suzuki; Hirohiko Kimura
Journal:  Radiol Phys Technol       Date:  2010-09-25

Review 3.  Imaging in liver transplantation.

Authors:  Settimo Caruso; Roberto Miraglia; Luigi Maruzzelli; Salvatore Gruttadauria; Angelo Luca; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

4.  Controversies in imaging of hepatocellular carcinoma: multidetector CT (MDCT).

Authors:  Paul M Silverman; Janio Szklaruk
Journal:  Cancer Imaging       Date:  2005-12-10       Impact factor: 3.909

5.  Findings of non-pathologic perfusion defects by CT arterial portography and non-pathologic enhancement of CT hepatic arteriography.

Authors:  Li Li; Pei-Hong Wu; Hao-Gao Lin; Jin-Qing Li; Yun-Xian Mo; Lie Zheng; Li-Xia Lu; Chao-Mei Ruan; Lin Chen
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

6.  Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma.

Authors:  Hideki Ohnishi; Kohsaku Sakaguchi; Kazuhiro Nouso; Yoshiyuki Kobayashi; Shinichiro Nakamura; Hironori Tanaka; Yasuhiro Miyake; Bon Shoji; Shouta Iwadou; Yasushi Shiratori
Journal:  Hepatol Int       Date:  2010-07-25       Impact factor: 6.047

7.  CT demonstration of the spontaneous regression of a hypervascular lesion in cirrhotic liver.

Authors:  A Luciani; A Rahmouni; H Achab; D Mathieu; N Jazaerli; M Bouanane
Journal:  Cancer Imaging       Date:  2001-02-01       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.